203 related articles for article (PubMed ID: 27240905)
1. Effect of a constant rate infusion of cytosine arabinoside on mortality in dogs with meningoencephalitis of unknown origin.
Lowrie M; Thomson S; Smith P; Garosi L
Vet J; 2016 Jul; 213():1-5. PubMed ID: 27240905
[TBL] [Abstract][Full Text] [Related]
2. Cytosine arabinoside constant rate infusion without subsequent subcutaneous injections for the treatment of dogs with meningoencephalomyelitis of unknown origin.
Stee K; Broeckx BJG; Targett M; Gomes SA; Lowrie M
Vet Rec; 2020 Nov; 187(11):e98. PubMed ID: 32862133
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial.
Jones BS; Liebel FX; Fadda A; Martin S; Lawn R; Lazzerini K; Harcourt-Brown T
J Vet Intern Med; 2024; 38(3):1618-1625. PubMed ID: 38700360
[TBL] [Abstract][Full Text] [Related]
4. Meningoencephalitis of unknown origin: investigation of prognostic factors and outcome using a standard treatment protocol.
Lowrie M; Smith PM; Garosi L
Vet Rec; 2013 May; 172(20):527. PubMed ID: 23462382
[TBL] [Abstract][Full Text] [Related]
5. Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs.
Zarfoss M; Schatzberg S; Venator K; Cutter-Schatzberg K; Cuddon P; Pintar J; Weinkle T; Scarlett J; Delahunta A
J Small Anim Pract; 2006 Oct; 47(10):588-95. PubMed ID: 17004951
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid and blood lactate concentrations as prognostic biomarkers in dogs with meningoencephalitis of unknown origin.
Portero M; Martínez de Merlo E; Pérez C; Benito M; Daza MA; Fragio C
Vet J; 2019 Dec; 254():105395. PubMed ID: 31836169
[TBL] [Abstract][Full Text] [Related]
7. Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside.
Menaut P; Landart J; Behr S; Lanore D; Trumel C
Vet Rec; 2008 Feb; 162(8):241-5. PubMed ID: 18296666
[TBL] [Abstract][Full Text] [Related]
8. A newly designed radiation therapy protocol in combination with prednisolone as treatment for meningoencephalitis of unknown origin in dogs: a prospective pilot study introducing magnetic resonance spectroscopy as monitor tool.
Beckmann K; Carrera I; Steffen F; Golini L; Kircher PR; Schneider U; Bley CR
Acta Vet Scand; 2015 Jan; 57(1):4. PubMed ID: 25637270
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology.
Levitin HA; Foss KD; Li Z; Reinhart JM; Hague DW; Fan TM
J Vet Pharmacol Ther; 2021 Sep; 44(5):696-704. PubMed ID: 34080695
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin.
Jones A; McGrath S; Gustafson DL
J Vet Pharmacol Ther; 2019 Nov; 42(6):588-592. PubMed ID: 31490575
[TBL] [Abstract][Full Text] [Related]
12. Treatment With Cytarabine at Initiation of Therapy With Cyclosporine and Glucocorticoids for Dogs With Meningoencephalomyelitis of Unknown Origin Is Not Associated With Improved Outcomes.
Barber R; Downey Koos L
Front Vet Sci; 2022; 9():925774. PubMed ID: 35754543
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation, diagnostic findings, prognostic factors, treatment and outcome in dogs with meningoencephalomyelitis of unknown origin: A review.
Cornelis I; Van Ham L; Gielen I; De Decker S; Bhatti SFM
Vet J; 2019 Feb; 244():37-44. PubMed ID: 30825893
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology.
Pastina B; Early PJ; Bergman RL; Nettifee J; Maller A; Bray KY; Waldron RJ; Castel AM; Munana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2018 Oct; 41(5):638-643. PubMed ID: 29761906
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for early death or euthanasia within 100 days of diagnosis in dogs with meningoencephalitis of unknown origin.
Lawn RW; Harcourt-Brown TR
Vet J; 2022 Sep; 287():105884. PubMed ID: 35987308
[TBL] [Abstract][Full Text] [Related]
16. Survival time and relapse in dogs with meningoencephalomyelitis of unknown origin treated with prednisolone and ciclosporin: a retrospective study.
Brady SL; Woodward AP; le Chevoir M
Aust Vet J; 2020 Oct; 98(10):491-498. PubMed ID: 32794230
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and magnetic resonance imaging findings in 11 dogs with eosinophilic meningoencephalitis of unknown aetiology.
Cardy TJA; Cornelis I
J Small Anim Pract; 2018 Jul; 59(7):422-431. PubMed ID: 29603737
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two regimens for the treatment of meningoencephalomyelitis of unknown etiology.
Smith PM; Stalin CE; Shaw D; Granger N; Jeffery ND
J Vet Intern Med; 2009; 23(3):520-6. PubMed ID: 19645837
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on meningoencephalomyelitis of unknown origin.
Coates JR; Jeffery ND
Vet Clin North Am Small Anim Pract; 2014 Nov; 44(6):1157-85. PubMed ID: 25239815
[TBL] [Abstract][Full Text] [Related]
20. Clinical Presentation, Diagnostic Findings, and Long-term Survival Time in 182 Dogs With Meningoencephalitis of Unknown Origin From Central Europe That Were Administered Glucocorticosteroid Monotherapy.
Paušová TK; Tomek A; Šrenk P; Belašková S
Top Companion Anim Med; 2021 Aug; 44():100539. PubMed ID: 33964477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
